NCT04274426 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04274426
Title	Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRalpha) High Recurrent Ovarian Cancer (MIROVA)
Acronym	MIROVA
Recruitment	Active, not recruiting
Gender	female
Phase	Phase II
Variant Requirements	No
Sponsors	AGO Research GmbH
Indications	ovary epithelial cancer ovarian carcinosarcoma fallopian tube cancer peritoneum cancer ovarian carcinoma
Therapies	Carboplatin + Paclitaxel Carboplatin + Gemcitabine Carboplatin + Pegylated liposomal doxorubicin Carboplatin + Mirvetuximab Soravtansine
Age Groups:	adult \| senior
Covered Countries	DEU

NCT04274426
Clinical Trial Detail